Over 80 Korean Pharmaceutical and Biotech Companies and Organizations to Participate
Focus on Expanding Client Connections and Raising Brand Recognition
South Korean pharmaceutical and biotech companies are set to participate in large numbers at the world's largest pharmaceutical and biotech exhibition, the "2025 BIO International Convention (BIO USA)," which will be held in Boston, United States, from June 16 to 19 (local time). Major contract development and manufacturing organizations (CDMOs) will promote their production capacity and quality competitiveness as they seek global contracts, while new drug development companies aim to raise the profile of "K-Bio" and explore opportunities for global collaboration.
According to the pharmaceutical and biotech industry on June 10, it is reported that about 80 domestic companies and organizations will participate in this year's BIO USA. Samsung Biologics, Celltrion, Lotte Biologics, SK Biopharmaceuticals, Dong-A ST, ST Pharm, ST GenBio, EuBiologics, and Inventage Lab will each have their own booths at the event.
BIO USA is organized annually by the Biotechnology Innovation Organization (BIO), rotating among major biotech clusters in the United States every June. This year's event will be held in Boston, Massachusetts, for four days, and more than 20,000 global pharmaceutical and biotech professionals are expected to attend.
Domestic CDMO companies plan to focus on expanding their contact points with new clients and raising their brand recognition during this opportunity. Samsung Biologics will showcase its world-leading 784,000-liter biopharmaceutical production capacity, as well as its expanded CDMO portfolio and artificial intelligence (AI)-based operations, to highlight its competitive edge.
Lotte Biologics will focus on promoting its antibody-drug conjugate (ADC) capabilities. The company will present the full-scale operation of its ADC production facility at the Syracuse Bio Campus in New York and unveil the blueprint for its first plant at the Songdo Bio Campus, which is scheduled for commercial production in 2027, to demonstrate its differentiated CDMO capabilities.
IDT Biologika, a German CDMO specializing in viral vaccines and a subsidiary of SK bioscience, will also participate. The company will introduce its integrated, customized service capabilities, which cover everything from the development to the manufacturing of viral vaccines, gene and immunotherapy products, and aseptic injectables, as well as a variety of partnership case studies.
Celltrion will also seek to discover new partners and promote its products. A Celltrion representative stated, "This year, we will again set up our own booth to promote our technological competitiveness, products, and brand," adding, "We also plan to identify potential partners for follow-up biosimilar products, new ADC drugs, and new multi-antibody drugs in development."
Dong-A ST, ST Pharm, and ST GenBio of the Dong-A Socio Group will set up a joint booth. The CEOs of all three companies will be present. Dong-A ST will focus on promoting new drug development, ST Pharm will highlight the expansion of new businesses such as guide RNA, and ST GenBio will actively promote its biosimilar CDMO business.
New drug development companies will also participate in the partnering program. ABL Bio, a company specializing in bispecific antibodies, will seek technology transfer and joint development partners at this year's BIO USA, featuring its Grabody-B blood-brain barrier (BBB) shuttle platform and 4-1BB-based bispecific antibody immuno-oncology drugs.
GoBioLab, a company specializing in microbiome-based new drug development, plans to seek various global collaboration opportunities such as joint development and technology transfer, and to strengthen its presence in the global market.
Pharos iBio, an AI-based innovative drug development company, will present its research achievements for "PHI-101," a next-generation acute myeloid leukemia (AML) treatment, and "PHI-501," a treatment for refractory solid tumors, as it seeks global collaboration opportunities.
Meanwhile, at this event, the global pharmaceutical and biotech industry will continue discussions on key issues such as next-generation cancer therapies and responses to changes in the global supply chain.
MSD (Merck & Co., USA) will discuss the development of cancer treatments through advances in precision medicine, immunotherapy, artificial intelligence, and data-driven diagnostics in a presentation titled "The Future of Cancer Treatment" on June 16, the first day of the exhibition. Sarah Kilpatrick, Vice President of Pfizer, will share her views on June 18 regarding the impact of the U.S. Inflation Reduction Act (IRA) on the pharmaceutical and biotech industry, as well as trends in innovative drug development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
